200 related articles for article (PubMed ID: 12870435)
1. Drug resistance mechanisms in cancer cells: a proteomics perspective.
Verrills NM; Kavallaris M
Curr Opin Mol Ther; 2003 Jun; 5(3):258-65. PubMed ID: 12870435
[TBL] [Abstract][Full Text] [Related]
2. Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents.
O'Connor R; Clynes M; Dowling P; O'Donovan N; O'Driscoll L
Expert Opin Drug Metab Toxicol; 2007 Dec; 3(6):805-17. PubMed ID: 18028026
[TBL] [Abstract][Full Text] [Related]
3. Casting light on molecular events underlying anti-cancer drug treatment: what can be seen from the proteomics point of view?
Kraljevic S; Sedic M; Scott M; Gehrig P; Schlapbach R; Pavelic K
Cancer Treat Rev; 2006 Dec; 32(8):619-29. PubMed ID: 17069979
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanisms of drug resistance.
Longley DB; Johnston PG
J Pathol; 2005 Jan; 205(2):275-92. PubMed ID: 15641020
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in clinical oncoproteomics.
Jain KK
J BUON; 2007 Sep; 12 Suppl 1():S31-8. PubMed ID: 17935275
[TBL] [Abstract][Full Text] [Related]
6. Oncoproteomics.
Joshi S; Tiwari AK; Mondal B; Sharma A
Clin Chim Acta; 2011 Jan; 412(3-4):217-26. PubMed ID: 20955692
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of apoptosis resistance and treatment strategies to overcome them in hormone-refractory prostate cancer.
Uzzo RG; Haas NB; Crispen PL; Kolenko VM
Cancer; 2008 Apr; 112(8):1660-71. PubMed ID: 18278811
[TBL] [Abstract][Full Text] [Related]
8. Prediction of broad spectrum resistance of tumors towards anticancer drugs.
Efferth T; Konkimalla VB; Wang YF; Sauerbrey A; Meinhardt S; Zintl F; Mattern J; Volm M
Clin Cancer Res; 2008 Apr; 14(8):2405-12. PubMed ID: 18413831
[TBL] [Abstract][Full Text] [Related]
9. Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death.
Hazlehurst LA; Landowski TH; Dalton WS
Oncogene; 2003 Oct; 22(47):7396-402. PubMed ID: 14576847
[TBL] [Abstract][Full Text] [Related]
10. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
11. Integrins and extracellular matrix: a novel mechanism of multidrug resistance.
Elliott T; Sethi T
Expert Rev Anticancer Ther; 2002 Aug; 2(4):449-59. PubMed ID: 12647988
[TBL] [Abstract][Full Text] [Related]
12. Multidrug resistance in cancer therapy: role of the microenvironment.
Galmarini CM; Galmarini FC
Curr Opin Investig Drugs; 2003 Dec; 4(12):1416-21. PubMed ID: 14763126
[TBL] [Abstract][Full Text] [Related]
13. Resistance mechanisms in human lung cancer.
Mattern J; Volm M
Invasion Metastasis; 1995; 15(3-4):81-94. PubMed ID: 8621273
[TBL] [Abstract][Full Text] [Related]
14. Use of proteomics to study chemosensitivity.
Poland J; Wandschneider S; Urbani A; Bernardini S; Federici G; Sinha P
Methods Mol Med; 2005; 111():267-81. PubMed ID: 15911985
[TBL] [Abstract][Full Text] [Related]
15. Bypassing cancer drug resistance by activating multiple death pathways--a proposal from the study of circumventing cancer drug resistance by induction of necroptosis.
Hu X; Xuan Y
Cancer Lett; 2008 Feb; 259(2):127-37. PubMed ID: 18082322
[TBL] [Abstract][Full Text] [Related]
16. Cancer proteomics and its application to discovery of therapy response markers in human cancer.
Smith L; Lind MJ; Welham KJ; Cawkwell L;
Cancer; 2006 Jul; 107(2):232-41. PubMed ID: 16752413
[TBL] [Abstract][Full Text] [Related]
17. Overcoming drug resistance in patients with metastatic breast cancer.
Wong ST; Goodin S
Pharmacotherapy; 2009 Aug; 29(8):954-65. PubMed ID: 19637949
[TBL] [Abstract][Full Text] [Related]
18. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers.
Sabbah M; Emami S; Redeuilh G; Julien S; Prévost G; Zimber A; Ouelaa R; Bracke M; De Wever O; Gespach C
Drug Resist Updat; 2008; 11(4-5):123-51. PubMed ID: 18718806
[TBL] [Abstract][Full Text] [Related]
19. [Research advance on role of tumor microenvironment in mediating acquired drug resistance].
Ma XL; Xing H; Ma D
Ai Zheng; 2007 Aug; 26(8):923-6. PubMed ID: 17697561
[TBL] [Abstract][Full Text] [Related]
20. Current strategies in overcoming resistance of cancer cells to apoptosis melanoma as a model.
Hersey P; Zhuang L; Zhang XD
Int Rev Cytol; 2006; 251():131-58. PubMed ID: 16939779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
